ERBB2 and neoplasm: In case of a combined pCR (ypT0/TisN0), an improved survival was observed for all subtypes, but especially for HER2+ tumor subtypes: HR+/HER2− (80.0 vs. 70.6%), HR+/HER2+ (91.7 vs. 72.4%), HR−/HER2+ (83.0 vs. 50.0%), HR−/HER2− (57.1 vs. 42.5%) (Table 4).